WOOJUNG BIO Calls Extraordinary General Meeting: Name Change, Business Diversification, New Inside Director Appointment Proposed

WOOJUNG BIO has resolved to hold an extraordinary general meeting on July 8, 2026, at 9:00 AM at its drug cluster in Hwaseong, Gyeonggi-do. The record date for voting is June 15, 2026.
Agenda 1-1: Amendment of Articles of Incorporation (Company Name Change) – The company plans to change its name by revising Article 1. The new name is not disclosed, but it appears to be a strategic move for brand enhancement or business expansion.
Agenda 1-2: Addition of Business Purposes – The company will add new business areas including cosmetics raw materials, pharmaceutical intermediates, food functional materials, animal health products, and related R&D and sales. This diversification may open new revenue streams in the long term but has limited immediate impact.
Agenda 2: Appointment of Inside Director Ham Seok-hee – Ham Seok-hee (born 1972), currently head of HR & General Affairs, is nominated as a new inside director for a 3-year term. This reflects strengthening of management expertise.
Agenda 3: Revision of Executive Severance Pay Regulations – The company proposes changes to severance pay rules, likely for cost management or governance transparency.
[AI Summary]All agenda items are routine corporate governance matters with no material impact on shareholder value in the near term. The name change and business purpose expansion are part of mid-to-long-term strategy but do not constitute a significant event affecting current valuation.